A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients

Data are mean ± standard deviation for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatmen. **p < 0.01 versus week 0 in systemic therapy-naive patients; †p < 0.05, ††p < 0.01 versus week 0 in systemic therapy-experienced patients, by repeated measures analysis of variance with Bonferroni’ s post hoc test. Supplementary Figure 3. Achievement rates of eczema area and severity index (EASI) 75, EASI 90, and EASI 100 in patients with atopic dermatitis treated with upadacitinib 15 mg or 30 mg.

Achievement rates of EASI 75, EASI 90, or EASI 100 are shown for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatment. Supplementary Figure 4. Achievement rates of peak pruritus-numerical rating scale (PP-NRS) 4, and atopic dermatitis control tool (ADCT) 7 in patients with atopic dermatitis treated with upadacitinib 15 mg or 30 mg.

Achievement rates of PP-NRS 4 and ADCT 7 are shown for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatment. Supplementary Figure 5. The transition of laboratory indexes in patients with atopic dermatitis treated with upadacitinib 15 mg or 30 mg.

Values of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), or total eosinophil count (TEC) are shown as medians for systemic therapy-naive patients (blue) and systemic therapy-experienced patients (orange) during the 96-week treatment.